BIO-Europe Spring

Next week our CEO, Jan Thirkettle, will be in Milan for #BIOEuropeSpring to discuss our lead Huntington’s disease program, which targets FAN1 nuclease - a key protective protein that helps slow the toxic cascade driving disease progression.

If you are interested in learning more about our targeted approach or therapeutic platform, reach out to Jan via the partnering portal to arrange a meeting.

More information about BIO-Europe Spring is here.

#BIOEuropeSpring

#HarnessTherapeutics #Biotech #Innovation #NeurodegenerativeDiseases #HuntingtonsDisease

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

September 2024

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

View all